The feed
GLP-1 briefs
Dated, plain-English notes on what actually moved this cycle — prices, supply, and provider changes across the GLP-1 telehealth market. Newest first. Each brief links onward to the underlying provider brief or the Brief Score methodology.
- Price
Flat-fee pricing holds while teaser tiers keep resetting
Our top-ranked desk kept its no-step-up rate for a third straight cycle. Intro-priced competitors, meanwhile, reset to full rate after month one — the gap teaser tiers never advertise.
- Supply
Both GLP-1 molecules stay off the FDA shortage list
Brand semaglutide and tirzepatide remain resolved on the FDA drug-shortage database. Compounded supply stays legal but under active regulatory attention, so who your provider sources from still matters.
- Price
Cheapest tracked tirzepatide slips again
One weight-focused program trimmed its tirzepatide rate to the lowest line on our board this cycle, widening its lead on the injection-averse crowd that also wants a sublingual route.
- Provider
A flat-fee pioneer drifts to the top of the price board
The provider that popularized flat-fee compounded GLP-1 now prices at the higher end of our tracker, a reminder that 'the original' is not automatically the cheapest anymore.
- Policy
How we score a provider's price stability
Price Stability is the heaviest factor in the Brief Score. Here is exactly how a steady, no-surprise monthly line earns points — and how a teaser rate that silently triples loses them.
Briefs are dated market observations, revised as the story moves — not timeless fact, and not medical advice. Confirm any current price or supply status at the source.